Measurement of non-VKA oral anticoagulants versus classic ones: The appropriate use of hemostasis assays

被引：34
作者：
Douxfils J. [1 ]
Tamigniau A. [2 ]
Chatelain B. [2 ]
Goffinet C. [3 ]
Dogné J.-M. [1 ]
Mullier F. [1 ,2 ]
机构：
[1] University of Namur, Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for LIfe Sciences (NARILIS), Namur
[2] Université Catholique de Louvain, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for LIfe Sciences (NARILIS), CHU Dinant Godinne UcL Namur, 1, avenue Dr Gaston Therasse, Yvoir
[3] Clinique et Maternité Sainte-Elisabeth, Namur
来源：
Thrombosis Journal | / 12卷 / 1期
关键词：
Apixaban; Dabigatran; Enoxaparin; Low molecular weight heparin; Monitoring; Non-VKA oral anticoagulants; Rivaroxaban; Vitamin K antagonist;
D O I：
10.1186/1477-9560-12-24
中图分类号：
学科分类号：
摘要：
Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux). Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or thromboembolic event during the treatment's period, in those with acute renal failure, in patients who require urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs. © 2014 Douxfils et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 146 条
[1]  
Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, pp. 1139-1151, (2009)
[2]  
Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, pp. 883-891, (2011)
[3]  
Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, pp. 981-992, (2011)
[4]  
Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L., Waldo A.L., Ezekowitz M.D., Weitz J.I., Spinar J., Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, pp. 2093-2104, (2013)
[5]  
Investigators E., Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Lensing A.W., Misselwitz F., Prins M.H., Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, pp. 2499-2510, (2010)
[6]  
Investigators E.-P., Buller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., Minar E., Chlumsky J., Verhamme P., Wells P., Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, pp. 1287-1297, (2012)
[7]  
Schulman S., Kakkar A.K., Goldhaber S.Z., Schellong S., Eriksson H., Mismetti P., Christiansen A.V., Friedman J., Le Maulf F., Peter N., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, pp. 764-772, (2014)
[8]  
Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Masiukiewicz U., Pak R., Thompson J., Raskob G.E., Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, pp. 799-808, (2013)
[9]  
Hokusai V.T.E.I., Buller H.R., Decousus H., Grosso M.A., Mercuri M., Middeldorp S., Prins M.H., Raskob G.E., Schellong S.M., Schwocho L., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, pp. 1406-1415, (2013)
[10]  
Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., Bandel T.J., Beckmann H., Muehlhofer E., Misselwitz F., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, pp. 2765-2775, (2008)
12345678910